The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience

Dybko, Jarosław; Jaźwiec, Bożena; Haus, Olga; Urbaniak-Kujda, Donata; Kapelko-Słowik, Katarzyna; Wróbel, Tomasz; Lonc, Tomasz; Sawicki, Mateusz; Mędraś, M; Kaczmar-Dybko, Agnieszka; Kuliczkowski, Kazimierz

doi:10.1155/2016/7531472

Cited by 6 publications

(2 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Thus, the Hasford score predicted prognosis accurately in 36 out of 37cases, and the positive predictive value of the scoring system is 97.29%. The results of the present study were in concordance with the results of the research done by Telen et al (2018) and Dybko et al (2016).…”

Section: Hasford Score As a Predictor And Actual Response In CMLsupporting

confidence: 94%

Clinicohematological study of spectrum of myeloproliferative neoplasms in a tertiary care hospital

Gupta

Kanetkar

2020

ijrps

View full text Add to dashboard Cite

Myeloproliferative neoplasms (MPNs) are a group of disorders of hematopoietic stem cells which were initially recognised by William Dameshek in 1951. Objectives of the study were to diagnose and classify cases of myeloproliferative neoplasms according to 2016 revision of WHO classification of myeloid neoplasms and acute leukaemias, to study various haematological parameters of cases of MPNs (Peripheral smear findings, bone marrow aspirate and trephine biopsy) and their clinical manifestations, to record the cytogenetic/molecular genetic abnormalities of the cases and to categorise CML patients according to Hasford Risk Score as a predictor of prognosis. This study was a prospective study carried out in the Department of Pathology of a tertiary care hospital over two years from June 2016 to September 2018. The study included a total of 41 cases of MPNs. The cases of CMLs were diagnosed on peripheral blood findings, Bone marrow aspiration, Trephine biopsy Serum LDH and uric acid. CML was the most common MPN encountered (37/41; 90.24%) in the present study. Maximum serum LDH elevation was observed in CML cases with a mean value of 1396.6 U/L. Of the 37 CML cases, as per Hasford score, 17 cases were categorised into a low-risk group, 17 cases into an intermediate-risk group and 3 cases into a high-risk group. In the present study of Hasford score in CML cases, it was found that it helps in making a better-informed decision about the adaption of alternative high-risk treatment, and was of value in oncology practice.

show abstract

Section: Hasford Score As a Predictor And Actual Response In CMLsupporting

confidence: 94%

Clinicohematological study of spectrum of myeloproliferative neoplasms in a tertiary care hospital

Gupta

Kanetkar

2020

ijrps

View full text Add to dashboard Cite

show abstract

“…7 Dybko stated that Hasford score was still usefull as a tool to differentiate low and intermediate risks in achieving molecular response where as Sokal and EUTOS did not. 8 To this day Sokal score was still the main score that was widely use, because of that researches in Hasford score was still need to be conducted.…”

Section: Introductionmentioning

confidence: 99%

Association between Hasford Scoring System and Hematologic Response in Chronic and Accelerated Phase of Chronic Myelocytic Leukemia Patient with Imatinib for Three Months

Purnomo

Bintoro

Sedana

et al. 2019

Mol Cell Biomed Sci

View full text Add to dashboard Cite

Background: Hasford score is a scoring system which was made in interferon treatment era to assess chronic myelocytic leukemia (CML) prognosis. Complete hematologic response (CHR) is the milestone of prognosis evaluation. CHR achievement will significantly increase survival. Imatinib is a revolutionized treatment that change the prognosis of CML. With the advent of Imatinib, lessened the prognostic impact of the Hasford score to predict prognosis.Materials and Methods: An observational analytic with prospective cohort study conducted in oncology outward division Dr. Soetomo hospital Surabaya, from July until October 2018. Hasford score determined in 32 patients at the beginning of the study, given imatinib and followed up regularly for 3 months to know the hematologic response. Data were analyzed using Fisher exact test which was considered significant if p<0.05.Results: Median age was 39 years old, male 37.5% and female 62.5%, the median spleen was 18 cm, median hemoglobin was 9.1 g/dL, median leukocyte was 180x109 /L, median thrombocyte was 645x109 /L, median eosinophil was 2.9%, median basophil was 4.6%, median myeloblast was 6%. Hasford score showed 3.1% in low risk, 25% in intermediate risk and 71.9% in high risk. As much as 78.1% complete hematologic response was found in patient, and 21.9% was incomplete.Conclusion: There was no association between Hasford scoring system and hematologic response in chronic and accelerated phase of chronic myelocytic leukemia patient with imatinib for three month. Hasford score had no impact in hematologic response with imatinib.Keywords: Hasford score, hematologic response, CML, imatinib

show abstract

Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients With Chronic Myeloid Leukemia

Seo

Hyun

et al. 2019

Clinical Lymphoma Myeloma and Leukemia

View full text Add to dashboard Cite

The Hasford Score May Predict Molecular Response in Chronic Myeloid Leukemia Patients: A Single Institution Experience

Cited by 6 publications

References 22 publications

Clinicohematological study of spectrum of myeloproliferative neoplasms in a tertiary care hospital

Clinicohematological study of spectrum of myeloproliferative neoplasms in a tertiary care hospital

Association between Hasford Scoring System and Hematologic Response in Chronic and Accelerated Phase of Chronic Myelocytic Leukemia Patient with Imatinib for Three Months

Tyrosine Kinase Inhibitor Dosing Patterns in Elderly Patients With Chronic Myeloid Leukemia

Contact Info

Product

Resources

About